Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 3/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 10/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 9/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 2/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | ULK1 | O75385 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15770097 | 0.91 | JAK3 (0.45) | JAK3LCK | |
| SCHEMBL15769548 | 0.91 | CDK1 (0.40) | JAK3PTK2LCKLRRK2 | |
| SCHEMBL15769485 | 0.90 | JAK3 (0.49) | JAK3PTK2PTK2BKCNH2LCK | |
| SCHEMBL15769772 | 0.90 | GRM5 (0.39) | JAK3LCK | |
| SCHEMBL15769401 | 0.88 | JAK2 (0.38) | JAK3LCK | |
| SCHEMBL15770094 | 0.88 | JAK3 (0.38) | JAK3LCK | |
| SCHEMBL15769154 | 0.87 | CDK1 (0.41) | JAK3PTK2LCKLRRK2 | |
| SCHEMBL15769385 | 0.86 | JAK3 (0.47) | JAK3PTK2PTK2BKCNH2 | |
| SCHEMBL15769468 | 0.83 | JAK3 (0.45) | JAK3KCNH2LCK | |
| SCHEMBL15769429 | 0.82 | JAK3 (0.45) | JAK3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2928891-B1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2019-02-20 | — | — | EP | claimed |
| US-9062068-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | claimed |
| US-20140163022-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2014-06-12 | — | — | US | claimed |
| EP-2928891-B1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-9913843-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-20150306100-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2015-10-29 | — | — | US | disclosed |
| US-9062068-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140163022-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163022-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | JAK3 572/4885PTK2 175/4885PTK2B 303/4885 |
| US-20150306100-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | JAK3 572/4885PTK2 175/4885PTK2B 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.